相关实验视频

Updated: Jan 8, 2026

Fluorescence Activated Cell Sorting FACS and Gene Expression Analysis of Fos-expressing Neurons from Fresh and Frozen Rat Brain Tissue

Fluorescence Activated Cell Sorting FACS and Gene Expression Analysis of Fos-expressing Neurons from Fresh and Frozen Rat Brain Tissue

Published on: August 27, 2016

投影定义的腹部体区域神经元表现出芬太尼诱导的分子和功能适应,这些不同支持药物背景协会

Annalisa Montemarano¹, Hajra Sohail¹, Logan D Fox¹

¹Department of Anesthesiology and Perioperative Medicine, Pennsylvania State University College of Medicine, Hershey PA.

bioRxiv : the preprint server for biology

|December 18, 2025

概括

像芬太尼尔这样的合成阿片类药物会导致持续性阿片类药物使用障碍 (OUD). 这项研究揭示了腹部体区域 (VTA) 神经元向不同的大脑区域投射的明显的大脑适应,影响了与芬太尼相关的行为.

科学领域:

神经科学是一个神经科学.
分子生物学分子生物学
药理学药理学是指药理学的学科.

背景情况:

阿片类药物使用障碍 (OUD) 是一种由合成阿片类药物驱动的关键公共卫生问题.
腹膜区域 (VTA) 对阿片类药物奖励至关重要,其投射到核 (NAc) 和前额皮层 (PFC).
对于多样化的VTA细胞类型如何协调以调解寻找药物的行为,人们的理解有限.

研究的目的:

在雄性和雌性小鼠中调查投影定义的VTA神经元对芬太尼的差异反应.
了解VTA神经突出如何编码与芬太尼相关的行为.
阐明OUD和合成阿片类药物成背后的神经机制.

主要方法:

RNA测序和加权基因共同表达网络分析以确定转录变化.
在体内进行成像,以监测神经元活动.
化学遗传学用于操纵VTA神经活动.

主要成果:

芬太尼在向NAc与PFC投射的VTA神经元中诱导了不一致的转录适应.
在条件化的位置偏好过程中,在VTA-NAc和VTA-PFC预测之间观察到不同的激活时间表.
这些发现表明,仅仅投射目标就决定了VTA神经元对芬太尼的适应.

结论:

VTA神经元对芬太尼等合成阿片类药物表现出投射特异性适应.
了解这些差异性适应是推进OUD治疗策略的关键.
这项研究为VTA在编码与阿片类药物相关的行为和成方面的作用提供了新的见解.

更多相关视频

A Conditioned Place Preference Protocol for Measuring Incubation of Craving in Rats

A Conditioned Place Preference Protocol for Measuring Incubation of Craving in Rats

Published on: November 6, 2018

Using Optogenetics to Reverse Neuroplasticity and Inhibit Cocaine Seeking in Rats

Using Optogenetics to Reverse Neuroplasticity and Inhibit Cocaine Seeking in Rats

Published on: October 5, 2021

相关概念视频

Drug Abuse and Addiction: Pharmacological Phenomena

Drug Abuse and Addiction: Pharmacological Phenomena

Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not...

Opioid Analgesics: Synthetic and Semisynthetic Opioids

Opioid Analgesics: Synthetic and Semisynthetic Opioids

Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...

Analgesia and Pain Management

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...

Opioid Receptors: Overview

Opioid Receptors: Overview

Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...